VRDN
Viridian Therapeutics Inc
20.50$
-0.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54,143.1% | -52,777.8% | -62,809.7% | -63,969.4% | -78,727.9% | -101,850.0% | -128,684.7% | -100,497.3% | -119.9% | -17,995.5% | -84,861.0% | -37,085.9% | -468.7% | |
| 187.5% | 208.3% | 201.4% | 197.2% | -14,670.9% | 170.8% | 162.5% | 150.7% | 0.2% | -657.6% | 85.8% | 41.2% | -0.7% | |
| 18,897.2% | 36,177.8% | 17,622.2% | 16,343.1% | 10,139.5% | 12,465.3% | 14,194.4% | 14,458.7% | 15.9% | 9,082.6% | 9,496.5% | 5,980.3% | 75.4% | |
| -5,670.8% | 7,800.0% | -6,886.1% | 15,455.6% | -7,174.4% | 638.9% | -19,243.1% | 21,153.3% | -85.5% | 61,628.0% | -15,170.2% | 1,186.3% | 4.2% | |
| 561.1% | 66.7% | 0.0% | 144.4% | 340.7% | 158.3% | 119.4% | 56.0% | 0.2% | 181.8% | 16.3% | 459.9% | 2.4% | |
| 66,723.6% | -235,709.7% | -198,673.6% | 86,077.8% | -98,450.0% | -87,381.9% | 138,975.0% | 100,957.3% | 178.7% | -257,136.4% | 54,795.0% | -81,393.3% | -516.3% | |
| – | 361.1% | 494.4% | – | 368.6% | – | – | 748.0% | 1.6% | -850.8% | – | – | – | |
| – | – | – | – | – | 0.0% | – | – | – | – | – | – | – | |
| 21,468.1% | 276,306.9% | 245,947.2% | 150.0% | 284,910.5% | 49,338.9% | 12,794.4% | 1,018.7% | 15.4% | 307,506.8% | 4,508.5% | 114,479.2% | 1,052.0% | |
| 34,048.6% | -12,180.6% | -15,536.1% | 22,258.3% | 107,732.6% | -139,893.1% | 23,084.7% | 1,478.7% | 74.1% | 32,375.0% | -25,557.4% | -4,000.0% | 67.0% | |
| -54,704.2% | -52,844.4% | -62,809.7% | -64,113.9% | -79,068.6% | -102,008.3% | -128,804.2% | -100,553.3% | -120.1% | -18,177.3% | -84,877.3% | -37,545.8% | -471.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.